Pfizer and AstraZeneca: what's next

Share this article:

Pfizer has until May 26 to make a hard offer to take over AstraZeneca, but the equivalent of kissing babies and shaking hands is ongoing. Reuters reports that the UK lawmakers will hear from both Pfizer CEO Ian Read and AstraZeneca CEO Pascal Soriot about the whys and why-nots of the merger, which will then be followed by another hearing May 14 about the scientific implications of the possible deal.

The companies have had a very public back-and-forth about the possible takeover, with AstraZeneca telling investors that the long game is a good one if the company stays on its own, while Pfizer has said AstraZeneca does not have the money to capitalize on its intellectual property.

While Jefferies analyst Jeffrey Holford noted last week that AstraZeneca has a spotty history of keeping its financial promises, Reuters noted Monday that Pfizer also carries financial baggage in the form of a long history of job cuts. AstraZeneca is nearing the tail-end of a sizeable staff cut which was spread out over several years, but critics of the proposed Pfizer-AstraZeneca deal are concerned it will trigger considerable layoffs abroad, and Reuters notes that Pfizer's layoff legacy includes cutting 1,700 jobs when it shut down research operations in Sandwich, in southern England.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Business Briefs

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.